Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva Pharmaceuticals has reached a settlement with the City and County of San Francisco regarding opioid-related claims, providing $24.8 million over 13 years and $20 million worth of generic Narcan over 10 years. This settlement, while not an admission of liability, aims to deliver life-saving treatments for opioid addiction. Previously, a California Superior Court judge found that Teva did not cause a public nuisance related to opioids in several counties. Teva continues to pursue a nationwide settlement in the interest of those benefiting from its medicines.
Teva Pharmaceutical Industries Ltd. announced the appointment of Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer, effective August 1, 2022. Dr. Hughes brings nearly 20 years of experience in drug development, previously serving at Vertex Pharmaceuticals and Novartis. His expertise in leading clinical development and collaborations is expected to enhance Teva's Global R&D initiatives. CEO Kåre Schultz expressed gratitude to former executive Dr. Hafrun Fridriksdottir for her 25 years of service while highlighting the potential growth opportunities with Dr. Hughes's leadership.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its second quarter 2022 financial results on July 27, 2022, at 7:00 a.m. ET. Following the release, a conference call and live webcast will take place at 8:00 a.m. ET. Interested participants can register here.
The live webcast can be accessed on Teva's website. A replay will be available within 24 hours.
Teva Pharmaceuticals announced promising interim results from its Pan-European Real World study (PEARL) at the European Academy of Neurology Congress in Vienna. The study, evaluating the effectiveness of AJOVY® (fremanezumab) for chronic and episodic migraine, showed that 54.7% of the 389 patients analyzed experienced a reduction of 50% or more in monthly migraine days over six months. The study aims to provide real-world evidence to improve treatment access and outcomes for migraine patients across diverse European populations.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Auspex Pharmaceuticals have settled a patent dispute with Aurobindo concerning Aurobindo's ANDA for a generic version of Teva's AUSTEDO (deutetrabenazine). The agreement ends the litigation in the U.S. District Court for New Jersey, allowing Aurobindo to sell its generic product starting in April 2033 or earlier under specific conditions. Teva asserts the agreement underscores the strength of its intellectual property for AUSTEDO, which treats chorea associated with Huntington's disease and tardive dyskinesia.
Teva Pharmaceuticals has released results from a retrospective U.S. study demonstrating the effectiveness of AJOVY (fremanezumab-vfrm) in reducing monthly migraine days when used with gepants for acute treatment. At study initiation, patients averaged 15.8 monthly migraine days, which decreased by 6.5 days (41.1% reduction) post-treatment. This data, presented at the 2022 AHS Annual Meeting, highlights AJOVY's potential in managing migraines across diverse patient populations. However, 9.1% of patients reported adverse events, including injection site reactions and uveitis.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced eight abstracts on the use of AJOVY (fremanezumab-vfrm) for migraine treatment at the 2022 American Headache Society Annual Meeting in Denver, June 9-12. Key presentations include a late-breaking study on AJOVY's effectiveness with gepants for acute treatment and subgroup analysis from the Phase 3b FOCUS study. The findings aim to highlight AJOVY's impact on patients with specific migraine treatment needs, particularly during Migraine Awareness Month.
STADA is launching Hukyndra®, a high-concentration, citrate-free biosimilar to adalimumab, in select European markets including France, Germany, Finland, and Sweden. This launch follows approval from the European Commission and represents the first product from STADA's partnership with Alvotech. Hukyndra® is designed to enhance patient comfort with reduced injection-site pain. The biosimilar is approved for treating various inflammatory conditions, supporting patient access to vital therapies in Europe.
Teva Pharmaceuticals, in partnership with Direct Relief and the National Association of Free and Charitable Clinics, has launched a $2 million program to enhance access to mental health care for underserved populations. The initiative will provide funding over two years to free clinics while donating generic medications for anxiety and depression. Initially focused on Florida, New Jersey, and California, this program aims to address health equity issues exacerbated by the COVID-19 pandemic, supporting clinics to provide necessary resources and care for uninsured patients.
Teva Pharmaceuticals has settled opioid-related claims with the Attorney General of West Virginia, agreeing to pay $75 million over 15 years and provide $27 million in the generic version of Narcan over 10 years. The settlement also includes $8 million for attorney fees. While this settlement advances efforts to address opioid addiction, it is not an admission of liability. Teva is negotiating a national settlement to further address ongoing litigation.